HealthDay News — The Pfizer-BioNTech COVID-19 vaccine is associated with a significantly lower risk for SARS-CoV-2 infection in pregnant women, according to a study published online July 12 in the Journal of the American Medical Association.

Inbal Goldshtein, PhD, from Maccabi Healthcare Services in Tel Aviv, Israel, and colleagues used data from a pregnancy registry (including 7530 vaccinated and 7530 matched unvaccinated women) to assess the association between receipt of the BNT162b2 mRNA vaccine and the risk for SARS-CoV-2 infection among pregnant women.

The researchers noted 118 SARS-CoV-2 infections in the vaccinated group and 202 in the unvaccinated group. In the vaccinated group, 83.8% were symptomatic vs 83.2% in the unvaccinated group (P ≥.99). However, in the 28 to 70 days of follow-up, there were 10 infections in the vaccinated group and 46 in the unvaccinated group, yielding hazards of infection of 0.33 and 1.64%, respectively (absolute difference: 1.31%; adjusted hazard ratio, 0.22). Sixty-eight patients reported vaccine-related adverse events, including headache (0.1%), general weakness (0.1%), nonspecified pain (less than 0.1%), and stomachache (less than 0.1%); no severe reactions were reported.

“In this retrospective cohort study of pregnant women, BNT162b2 mRNA vaccination compared with no vaccination was associated with a significantly lower risk of SARS-CoV-2 infection,” the authors write. “Interpretation of study findings is limited by the observational design.”


Continue Reading

Abstract/Full Text